President and CEO of Myokardia Inc (30-Year Financial, Insider Trades) Anastasios Gianakakos (insider trades) sold 12,687 shares of MYOK on 01/06/2020 at an average price of $68.45 a share. The total sale was $868,425.
MyoKardia Inc is a clinical stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardia Inc has a market cap of $3.27 billion; its shares were traded at around $70.79 with and P/S ratio of 229.85. GuruFocus has detected 2 severe warning signs with MyoKardia Inc. .
CEO Recent Trades:
- President and CEO Anastasios Gianakakos sold 12,687 shares of MYOK stock on 01/06/2020 at the average price of $68.45. The price of the stock has increased by 3.42% since.
- President and CEO Anastasios Gianakakos sold 5,000 shares of MYOK stock on 01/03/2020 at the average price of $71.8. The price of the stock has decreased by 1.41% since.
CFO Recent Trades:
- CFO Taylor C. Harris sold 1,683 shares of MYOK stock on 01/06/2020 at the average price of $68.45. The price of the stock has increased by 3.42% since.
Directors and Officers Recent Trades:
- Chief Business Officer Jake Bauer sold 2,466 shares of MYOK stock on 01/06/2020 at the average price of $68.45. The price of the stock has increased by 3.42% since.
- Chief Scientific Officer Robert Scott Mcdowell sold 2,650 shares of MYOK stock on 01/06/2020 at the average price of $68.45. The price of the stock has increased by 3.42% since.
- General Counsel Cynthia J Ladd sold 1,849 shares of MYOK stock on 01/06/2020 at the average price of $68.45. The price of the stock has increased by 3.42% since.
- Chief Business Officer Jake Bauer sold 18,916 shares of MYOK stock on 12/20/2019 at the average price of $70.07. The price of the stock has increased by 1.03% since.
For the complete insider trading history of MYOK, click here
.
